The U.S. Food and Drug Administration has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) subcutaneous injections for the treatment of generalized myasthenia gravis (gMG) in adult ...
Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART Hytrulo gMG patients on VYVGART achieve rapid, substantial, and sustained efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results